Table 4. Stable disease ≥ 6 months or partial response (PR) by RECIST and characterization by patient.

	Cancer Type	Dose Level	Best Response by RECIST 1.0	# of Prior Cytotoxic Regimens	Duration of Treatment (Weeks)	PTEN mut*	PIK3CA mut	RAS mut	RAF mut	P53 mut
9ζ	HNSCC	1	−29%	2	40	N	N	N	N	N
35	Chondrosarcoma	2	−2%	4	40	N	N	N	N	N
42Δ	Adenocarcinoma of the tongue	2	−7%	5	32	N	N	N	N	Y
46ζ	HNSCC	2	−54%	2	16	N	N	N	N	N
48	HNSCC	2	−35%	3	28	N	N	N	N	N
59	Melanoma	2	+3%	3	32	N	N	N	N	ND

Abbreviations: N, no mutation; Mut, mutation; ND, not done; HNSCC, squamous cell carcinoma of the head and neck; P, present.

^*PTEN loss by immunohistochemistry was not performed.

^Δindicates a patient with prior temsirolimus and bevacizumab treatment.

^ζindicates a patient with prior cetuximab treatment.